The objective of the present invention is to provide a method for efficiently supporting a thiol group-including compound on an insoluble base material. The method for supporting a thiol group-including compound on an insoluble base material according to the present invention is characterized in comprising Step A: treating the thiol group-including compound with a thiol group-including organic reducing agent and an inorganic reducing agent, and Step B: contacting a reaction liquid of said Step A with the insoluble base material.

The present invention relates to a peptide capable of binding to rheumatoid arthritis autoantibodies, which is a consecutive 10-25 amino acid sequence of any one fragment of the group consisting of SEQ ID NO: 3-4, 7-13 or 16-19, wherein the peptide fragment has an epitope that binds to the rheumatoid arthritis autoantibodies. Furthermore, the peptide fragment bound to the rheumatoid arthritis autoantibodies is used for testing rheumatoid arthritis, and according to this use, the present invention provides a method for testing rheumatoid arthritis disease and a test reagent kit used for determining whether a subject to be tested suffers from rheumatoid arthritis disease.

The application relates to an HCV recombinant antigen and a mutant thereof. The application provides an HCV recombinant antigen, the HCV recombinant antigen including at least 1 NS3 antigen, wherein at least one cysteine of the NS3 antigen in positions 1192-1517 of an HCV amino acid sequence is mutated into G and/or A, and preferably mutated into A. The application further provides a nucleic acid encoding the HCV recombinant antigen, an expression vector including the nucleic acid, a host cell including the expression vector, a conjugate including the HCV recombinant antigen, and a kit including the HCV recombinant antigen.

The application relates to an HCV recombinant antigen and a mutant thereof. The application provides an HCV recombinant antigen, the HCV recombinant antigen including at least 1 NS3 antigen, wherein at least one cysteine of the NS3 antigen in positions 1192-1517 of an HCV amino acid sequence is mutated into G and/or A, and preferably mutated into A. The application further provides a nucleic acid encoding the HCV recombinant antigen, an expression vector including the nucleic acid, a host cell including the expression vector, a conjugate including the HCV recombinant antigen, and a kit including the HCV recombinant antigen.

The disclosed technology relates to a method of immobilising a protein on a substrate. The disclosed technology further relates to the substrate comprising the immobilised protein, the use of the substrate in a wound dressing, and the use of the wound dressing in a method of treating a wound.

The disclosed technology relates to a method of immobilising a protein on a substrate. The disclosed technology further relates to the substrate comprising the immobilised protein, the use of the substrate in a wound dressing, and the use of the wound dressing in a method of treating a wound.

The present invention provides an improved method of quantitative and/or qualitative analysis of a target molecule using nitrocellulose membrane (NCM). In particular, the present invention provides a porous nitrocellulose membrane that includes a surface and an organic nanostructured molecule that is non-covalently attached to the surface of NCM. The organic nanostructured molecule has a branched region that includes a plurality of terminal region (e.g., terminal end) moieties that are non-covalently attached or bound to a surface of the porous NCM. The organic nanostructured molecule also comprises a linear region that includes a covalently attached capture molecule that is adapted to selectively bind to a target molecule. The NCM of the invention provides an improved reproducibility, reliability, and selectivity compared an NCM in the absence of the organic nanostructured molecule.

One embodiment of the present invention is a protein having affinity for an immunoglobulin, which is a protein having two or more domains derived from any of the amino acid sequences of E, D, and A domains of protein A, and in the amino acid sequence of at least one of the domains, one or more lysines are included, and the C-terminal lysine is deleted or substituted, or a protein having affinity for an immunoglobulin, which is a protein having two or more domains derived from any of B, C, and Z domains of protein A, and in the amino acid sequence of at least one of the domains, one or more lysines are included, and lysine at position 4 and the C-terminal lysine are deleted or substituted.

One embodiment of the present invention is a protein having affinity for an immunoglobulin, which is a protein having two or more domains derived from any of the amino acid sequences of E, D, and A domains of protein A, and in the amino acid sequence of at least one of the domains, one or more lysines are included, and the C-terminal lysine is deleted or substituted, or a protein having affinity for an immunoglobulin, which is a protein having two or more domains derived from any of B, C, and Z domains of protein A, and in the amino acid sequence of at least one of the domains, one or more lysines are included, and lysine at position 4 and the C-terminal lysine are deleted or substituted.

The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.